Kyntra Bio registers Phase 3 roxadustat trial for anemia in lower-risk MDS
A new Phase 3 study of oral roxadustat for transfusion-dependent lower-risk MDS anemia was listed as not yet recruiting, with a 2027 start planned.
The week's only update is a newly registered late-stage trial for Kyntra Bio's roxadustat program in myelodysplastic syndromes.
- Kyntra Bio registered a Phase 3, randomized, placebo-controlled trial (NCT07722988) of roxadustat (FG-4592) for anemia due to very low, low, or intermediate risk myelodysplastic syndromes in participants with high red blood cell transfusion burden.1 The study is not yet recruiting, with an estimated start date of April 2027 and estimated primary completion in September 2030.1 It plans to enroll 201 participants1 and its primary endpoint measures the percentage of participants with red blood cell-transfusion independence over any consecutive 56-day period, assessed from week 1 through week 24.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.